Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. 詳細を表示
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc...
PITTSBURGH, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...
PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella”) will participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York...
Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study...
LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancerNovel MRI contrast agent, which received support from National Institute of Diabetes and Digestive and...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0237 | 6.01217656012 | 0.3942 | 0.4378 | 0.39 | 177959 | 0.41242548 | CS |
4 | -0.0172 | -3.95311422661 | 0.4351 | 0.53 | 0.3775 | 823481 | 0.44356784 | CS |
12 | -0.06 | -12.5549278092 | 0.4779 | 1.5 | 0.3234 | 3919208 | 0.84478406 | CS |
26 | -0.2981 | -41.6340782123 | 0.716 | 1.5 | 0.3234 | 1842115 | 0.84199525 | CS |
52 | -0.5421 | -56.46875 | 0.96 | 2.71 | 0.3234 | 1138193 | 1.0522153 | CS |
156 | -6.6021 | -94.047008547 | 7.02 | 7.72 | 0.3234 | 771194 | 1.39771784 | CS |
260 | -6.6021 | -94.047008547 | 7.02 | 7.72 | 0.3234 | 771194 | 1.39771784 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約